Last $13.07 USD
Change Today +0.55 / 4.39%
Volume 228.3K
PETX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Open
$12.75
Previous Close
$12.52
Day High
$13.18
Day Low
$12.65
52 Week High
02/11/14 - $25.50
52 Week Low
10/2/14 - $9.20
Market Cap
453.6M
Average Volume 10 Days
235.6K
EPS TTM
$-0.62
Shares Outstanding
34.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARATANA THERAPEUTICS INC (PETX)

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

25 Employees
Last Reported Date: 03/26/14
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $50.7K
Chief Development Officer
Total Annual Compensation: $286.1K
Chief Commercial Officer
Total Annual Compensation: $270.6K
Chief Scientific Officer
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics Initiates Pivotal Study for AT-003

Aratana Therapeutics, Inc. announced the initiation of the pivotal field effectiveness study for AT-003, the company's innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc. AT-003 is an extended release injectable formulation of bupivacaine. The randomized, blinded, multicenter pivotal study will enroll approximately 150 client-owned dogs undergoing knee surgery and will be conducted under a study protocol for which Aratana received concurrence from the FDA's Center for Veterinary Medicine (CVM). Â Dogs participating in the study will be given AT-003 or placebo. Efficacy endpoints will be based on pain evaluation at 24-hour intervals up to 72 hours after surgery, as indicated by the Glasgow Composite Measuring Scale, a well validated and widely used scoring system.

Aratana Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2014 Animal Health Summit, Dec-11-2014 08:55 AM

Aratana Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2014 Animal Health Summit, Dec-11-2014 08:55 AM. Venue: Bank of America Conference Center, Boston, Massachusetts, United States. Speakers: Steven St. Peter, Co-Founder, Chief Executive Officer, President and Director.

Aratana Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 09:30 AM

Aratana Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 09:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Steven St. Peter, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $13.07 USD +0.55

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.78 USD -0.01
View Industry Companies
 

Industry Analysis

PETX

Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 572.3x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 484.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit www.aratana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.